Suvretta Capital Management LLC Has $113.17 Million Stock Position in Benitec Biopharma Inc. (NASDAQ:BNTC)

Suvretta Capital Management LLC boosted its stake in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 1.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,960,009 shares of the biotechnology company's stock after buying an additional 130,956 shares during the period. Benitec Biopharma accounts for 3.9% of Suvretta Capital Management LLC's portfolio, making the stock its 5th biggest holding. Suvretta Capital Management LLC owned about 38.59% of Benitec Biopharma worth $113,165,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Franklin Resources Inc. grew its stake in shares of Benitec Biopharma by 269.0% in the 4th quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock worth $37,123,000 after purchasing an additional 2,142,643 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Benitec Biopharma by 198.5% during the fourth quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock worth $33,268,000 after buying an additional 1,739,904 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in Benitec Biopharma by 134.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock worth $24,913,000 after buying an additional 1,131,129 shares during the last quarter. Geode Capital Management LLC grew its position in Benitec Biopharma by 134.7% in the fourth quarter. Geode Capital Management LLC now owns 197,096 shares of the biotechnology company's stock worth $2,490,000 after buying an additional 113,109 shares during the last quarter. Finally, Lion Point Capital LP increased its holdings in shares of Benitec Biopharma by 59.0% in the fourth quarter. Lion Point Capital LP now owns 62,000 shares of the biotechnology company's stock valued at $783,000 after buying an additional 23,000 shares in the last quarter. Institutional investors and hedge funds own 52.19% of the company's stock.

Insider Buying and Selling at Benitec Biopharma

In other Benitec Biopharma news, Director Suvretta Capital Management, L acquired 900,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $13.00 per share, for a total transaction of $11,700,000.00. Following the completion of the acquisition, the director now owns 8,793,245 shares of the company's stock, valued at approximately $114,312,185. This trade represents a 11.40% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.30% of the company's stock.

Wall Street Analysts Forecast Growth

BNTC has been the subject of several research reports. HC Wainwright reissued a "buy" rating and set a $28.00 price objective on shares of Benitec Biopharma in a research note on Monday. JMP Securities reaffirmed a "market outperform" rating and set a $20.00 target price on shares of Benitec Biopharma in a report on Thursday, May 15th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Benitec Biopharma has a consensus rating of "Buy" and a consensus target price of $24.71.

Benitec Biopharma Stock Performance

NASDAQ:BNTC traded down $0.05 during trading hours on Tuesday, hitting $13.93. 35,671 shares of the company's stock traded hands, compared to its average volume of 40,933. The stock's fifty day moving average price is $13.65 and its two-hundred day moving average price is $12.07. The firm has a market cap of $356.61 million, a P/E ratio of -9.23 and a beta of 0.34. Benitec Biopharma Inc. has a twelve month low of $5.74 and a twelve month high of $16.90.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.12. On average, equities research analysts predict that Benitec Biopharma Inc. will post -1.48 earnings per share for the current year.

Benitec Biopharma Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.